Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.67 |
| ▸ | CA7 | P43166 | 1/20 | 0.67 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4724826 | 0.82 | CA12 (1.00) | CA12CA7CA14TSHRSMN1; SMN2 | |
| SCHEMBL2430488 | 0.79 | CA12 (0.67) | CA12CA7CA14TSHRSMN1; SMN2 | |
| SCHEMBL27328264 | 0.79 | CA12 (0.59) | CA12CA7CA14TSHRSMN1; SMN2 | |
| SCHEMBL27328188 | 0.79 | CA12 (0.59) | CA12CA7CA14TSHRSMN1; SMN2 | |
| SCHEMBL12793315 | 0.78 | ALDH1A1 (0.78) | SMN1; SMN2ALDH1A1KMT2AMEN1POLB | |
| SCHEMBL16026491 | 0.75 | KDM4E (0.57) | L3MBTL1ALDH1A1KMT2AMEN1POLB | |
| SCHEMBL23475113 | 0.75 | CA12 (0.59) | CA12CA7CA14TSHRSMN1; SMN2 | |
| SCHEMBL14699661 | 0.75 | CA12 (0.59) | CA12CA7CA14TSHRSMN1; SMN2 | |
| SCHEMBL3183107 | 0.75 | TSHR (1.00) | CA12CA7CA14TSHRSMN1; SMN2 | |
| SCHEMBL17339932 | 0.74 | CA12 (0.73) | CA12CA7CA14TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306069-A1 | Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S | ASTEX THERAPEUTICS LIMITED (UK) | 2008-12-11 | — | — | US | disclosed |
| US-20080306069-A1 | Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S | ASTEX THERAPEUTICS LIMITED (UK) | 2008-12-11 | — | — | US | disclosed |
| WO-2006077414-A1 | PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306069-A1 | Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S | GSK3A, CDK11A, CDK1 | CA12 4108/4885CA7 4018/4885CA14 3914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.